Article Text

Download PDFPDF
Randomised controlled trial
Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests PPT is a consultant for Amgen, AstraZeneca, Kowa, Merck and Novartis. PPT is also involved in speaker's bureau activities for Amarin, AstraZeneca, Genzyme, GSK, Kowa and Merck.

  • Provenance and peer review Commissioned; internally peer reviewed.